Metro Infectious Diseases Consultants L.L.C. ( Site 5653) — Decatur, Georgia

Metro Infectious Diseases Consultants L.L.C. ( Site 5653) is a clinical research site located in Decatur, Georgia, United States 30033.

Crixeo Clinical Trials Trust Score: 11/100 (FAILING). This profile has not yet been claimed by the site owner.

Metro Infectious Diseases Consultants L.L.C. ( Site 5653) has participated in 2 clinical trials with 2 currently active.

Therapeutic areas: HIV-1 Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

Sponsors: Merck Sharp & Dohme LLC.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in Decatur

Browse all research sites in Georgia · View every site in Decatur

Sponsor Feasibility Report

Trust Score: 11/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Metro Infectious Diseases Consultants L.L.C. ( Site 5653)?

Metro Infectious Diseases Consultants L.L.C. ( Site 5653) has a Crixeo Trust Score of 11/100 (FAILING). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Metro Infectious Diseases Consultants L.L.C. ( Site 5653) conducted?

Metro Infectious Diseases Consultants L.L.C. ( Site 5653) has 2 clinical trials on record, with 2 currently active. Their work covers HIV-1 Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection.

Is Metro Infectious Diseases Consultants L.L.C. ( Site 5653) accredited by Crixeo Clinical Trials?

Metro Infectious Diseases Consultants L.L.C. ( Site 5653) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Metro Infectious Diseases Consultants L.L.C. ( Site 5653)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.